JAJeniffer Paola Tonato Alava

Jeniffer Paola Tonato Alava

*This is an algorithmically generated author record based on publicly available information.

Jeniffer Paola Tonato Alava has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • INTELIGENCIA ARTIFICIAL EXPLICABLE EN EL LABORATORIO CLÍNICO: OPORTUNIDADES Y BARRERAS PARA MEJORAR LA PRECISIÓN DIAGNÓSTICA Y LA SEGURIDAD DEL PACIENTE

    by Marco Vinicio Flores Blacio, Noemí Elizabeth Aroca Rivera, Jeniffer Paola Tonato Alava, Gabriela Ginely Lojano Ocampo

    Artificial intelligence (AI) has been progressively incorporated into clinical laboratories as a tool to support data processing, result interpretation, and diagnostic decision-making. However, the use of complex models has raised concerns regarding transparency, interpretability, and the ability to supervise algorithmic decisions, particularly when these decisions may influence patient care and safety. In this context, explainable artificial intelligence (XAI) has gained relevance by providing mechanisms intended to facilitate the understanding of predictions generated by AI models. This review aimed to analyze the opportunities and barriers associated with the application of XAI in the clinical laboratory, considering its potential contribution to diagnostic accuracy and patient safety. A descriptive and analytical bibliographic review was conducted of scientific literature published mainly between January 2021 and September 2026 through searches in PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, SpringerLink, and Google Scholar. Studies addressing explainable artificial intelligence, laboratory medicine, diagnosis, accuracy, validation, patient safety, and interpretability were considered. The reviewed evidence showed potential applications of XAI across the preanalytical, analytical, and postanalytical phases, as well as in hematology, biochemistry, microbiology, immunology, and digital pathology. The main opportunities included increased model transparency, traceability of predictions, support for error identification, and strengthened professional oversight. The main barriers involved data quality and heterogeneity, interoperability, external validation, bias, information protection, the lack of standardized explainability criteria, and the need for professional training. It was concluded that XAI represented a complementary tool with potential to support diagnostic accuracy and patient safety, provided that its implementation was accompanied by rigorous validation, continuous monitoring, human oversight, and appropriate ethical and regulatory criteria.

  • Open Access

    DIABETES MELLITUS TIPO 2 Y ENFERMEDAD RENAL CRÓNICA: FACTORES ASOCIADOS Y ESTRATEGIAS DE PREVENCIÓN BASADAS EN LA EVIDENCIA

    by Telmo Eduardo Salas Joya, Jeniffer Paola Tonato Alava, Oscar Santiago Palomeque Teran, María Belén Alvarez Mosquera

    La diabetes mellitus tipo 2 (DM2) representa una de las principales enfermedades crónicas no transmisibles y constituye un importante problema de salud pública debido a su elevadísima prevalencia y a sus complicaciones, entre ellas la enfermedad renal crónica (ERC), una de las principales causas de la insuficiencia renal terminal. La variabilidad de la evidencia sobre los factores asociados y las estrategias preventivas justifican la necesidad de sintetizar el conocimiento existente. El objetivo fue analizar los factores asociados entre la DM2 y la ERC y las estrategias de prevención sustentadas en la evidencia científica. Se realizó una revisión bibliográfica descriptiva, analítica y documental sustentada en las directrices PRISMA 2020. El proceso de búsqueda se realizó en las bases de datos PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, SpringerLink, Wiley Online Library y Cochrane Library, así como en guías internacionales. En los resultados se encontro como principales factores asociados el mal control glucémico, la hipertensión arterial, la obesidad, la dislipidemia, la edad avanzada y los inadecuados estilos vida. También se rescataron el control metabólico integral, las modificaciones de los estilos de vida, el tamizaje periódico de la función renal y el uso de fármacos nefroprotectores por sus beneficios clínicos. En conclusión, la prevención precoz y el abordaje multidisciplinario logran retrasar la progresión de la ERC y mejoran el pronóstico de los pacientes con DM2.